Innovator ETFs Trust Innovator Premium Income 15 Buffer ETF - January (BATS: LJAN)

Latest news for Innovator ETFs Trust Innovator Premium Income 15 Buffer ETF - January (BATS:LJAN)

The Fund is an actively managed exchange-traded fund (ETF) that invests in U.S. Treasury bills (the U.S. Treasuries) and FLexible EXchange Options (FLEX Options) that use as a reference asset, the SPDR S&P 500 ETF Trust (the Underlying ETF). Due to the unique mechanics of the Funds strategy, the return an investor can expect to receive from an investment in the Fund has characteristics that are distinct from many other investment vehicles. It is important that an investor understand the characteristics of the Fund before making an investment in the Fund. As further described below, the Funds principal investment strategy seeks to provide the following investment profile over an approximately one-year period from January 1 through December 31 of the current year (the Outcome Period)

Innovator Premium Income 15 Buffer ETF - January

Innovator ETFs Trust Innovator Premium Income 15 Buffer ETF - January

Citigroup analyst Atif Malik maintains Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) with a Buy and raises the price target from $62 to $64.

News

Price Target

Analyst Ratings

CSCO

Citigroup Maintains Buy on Cisco Systems, Raises Price Target to $64

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy and maintains $77 price target.

Reiteration

CAPR

HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $77 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Armata Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMP#AMEX">ARMP</a>) with a Buy and maintains $7 price target.

ARMP

HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $7 Price Target

In the current market session, First Solar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) share price is at $185.90, after a 2.07% increase. Moreover, over the past month, the stock decreased by 6.68%, but in the past year, went up by 22.43%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1731608109_0.png" alt="Past Year Chart" />

<h3>A Look at First Solar P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 63.99 in the Semiconductors &amp; Semiconductor Equipment industry, First Solar Inc. has a lower P/E ratio of 15.69. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1731608109_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

FSLR

P/E Ratio Insights for First Solar

Barclays analyst Brandon Oglenski maintains Spirit Airlines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NYSE">SAVE</a>) with a Underweight and lowers the price target from $3 to $0.5.

SAVE

Barclays Maintains Underweight on Spirit Airlines, Lowers Price Target to $0.5

HC Wainwright &amp; Co. analyst Mike Colonnese maintains HIVE Digital Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>) with a Buy and raises the price target from $5 to $8.

HIVE

HC Wainwright & Co. Maintains Buy on HIVE Digital Technologies, Raises Price Target to $8

The action in Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) has some investors and traders confused. The company released its earnings report Thursday<a href="https://www.benzinga.com/news/earnings/24/11/41972250/advance-auto-parts-q3-earnings-miss-new-strategy-outlook-more"> and it was well short of estimates</a>.
But the shares are trading higher. This is why it is our Stock of the Day.
The company reported a loss of four cents per share. This was well below the Street's estimates of a profit of 49 cents. The revenue was also well short of estimates. It came in at $2.15 billion. Analysts were looking for $2.65 billion.
But sometimes the headlines don't tell the whole story.
Operating margin is an important metric studied by analysts. It is a measurement of how profitable a company is.
For example, if a company has an operating margin of 5%, after all costs and expenses, it makes five cents for every dollar of sales. If the margin is 7%, it makes seven cents on every dollar of sales, and so on.
If the operating margin is increasing, it means the company is becoming more efficient and profitable.
Advance Auto's management team predicts an operating margin of 2%-3% in 2025. But their guidance for 2027 is 7%. So, despite current losses, some investors are buying shares because they believe the company will turn things around and that the long-term picture is bullish.
Read Also: <a href="https://www.benzinga.com/24/11/41976312/hillenbrand-posts-better-than-expected-earnings-joins-beazer-homes-tapestry-walt-disney-and-other-big-stocks-moving-higher-on-thursday">Hillenbrand Posts Better-Than-Expected Earnings, Joins Beazer Homes, Tapestry, Walt Disney And Other Big Stocks Moving Higher On Thursday</a>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="522" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14130516/AdvanceAutoParts-1024x522.png" alt="" class="wp-image-648705" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14130516/AdvanceAutoParts-1024x522.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14130516/AdvanceAutoParts-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14130516/AdvanceAutoParts-768x392.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14130516/AdvanceAutoParts-1536x784.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14130516/AdvanceAutoParts.png 1582w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
As you can see on the chart, the stock may be breaking out.
Resistance is a large concentration of sell orders that are at, or close to, the same price. Uptrends tend to end and even reverse when they reach resistance.
This was the case with Advanced Auto in September.
If the price eventually moves above resistance, traders say it is a &#8220;breakout.&#8221; This isn't just symbolic. It illustrates an important supply and demand dynamic.
It shows the investors and traders who created the resistance are gone. They have either canceled or finished their orders. This means a large amount of supply has left the market.
This could set the stage for a move higher.
If new buyers enter the market, they will have a hard time finding someone to buy shares from. As a result, they will be forced to pay higher prices to get the interest of sellers. This could force the stock into an uptrend.
On Wall Street, the headlines may not tell the whole story and the initial reaction may be wrong. This could be the case with Advance Auto.
Read Next: • <a href="https://www.benzinga.com/news/earnings/24/11/41962884/us-stocks-settle-mixed-following-inflation-data-investor-sentiment-improves-but-fear-index-remains-in-greed-zone">U.S. Stocks Settle Mixed Following Inflation Data: Investor Sentiment Improves, But Fear Index Remains In &#8216;Greed&#8217; Zone</a>
Photo: Refina via Shutterstock

Technicals

Trading Ideas

Stock Of The Day: Why Is Advance Auto Rallying On A Loss?

ELVA

Trading Halt: Halt status updated at 1:10:00 PM ET: Quotation Resumption: News and Resumption Times

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>) with a Buy and lowers the price target from $5 to $1.5.

XFOR

HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $1.5

Barclays analyst Brandon Oglenski maintains United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) with a Overweight and raises the price target from $75 to $150.

Barclays Maintains Overweight on United Airlines Holdings, Raises Price Target to $150

B of A Securities analyst Michael Cherny downgrades Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) from Buy to Underperform.

Downgrades

Hims & Hers Health, Inc. Class A Common Stock

HIMS

B of A Securities Downgrades Hims & Hers Health to Underperform

Barclays analyst Brandon Oglenski maintains Sun Country Airlines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCY#NASDAQ">SNCY</a>) with a Overweight and raises the price target from $20 to $24.

SNCY

Barclays Maintains Overweight on Sun Country Airlines, Raises Price Target to $24

WYNN

Wynn Resorts 13G Filing Shows Susquehanna Securities, LLC Reported A 5.6% Stake In The Co As Of September 30, 2024

HC Wainwright &amp; Co. analyst Mike Colonnese maintains Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) with a Buy and raises the price target from $26 to $35.

HC Wainwright & Co. Maintains Buy on Hut 8, Raises Price Target to $35

Barclays analyst Brandon Oglenski maintains JetBlue Airways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) with a Underweight and raises the price target from $5 to $7.

JBLU

Barclays Maintains Underweight on JetBlue Airways, Raises Price Target to $7

Inter &amp; Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTR#NASDAQ">INTR</a>) reported quarterly sales of $340.00 million which beat the analyst consensus estimate of $314.68 million by 8.05 percent. This is a 28.27 percent increase over sales of $265.06 million the same period last year.

Earnings

Earnings Beats

INTR

Inter & Co Q4 Sales $340.00M Beat $314.68M Estimate

Barclays analyst Brandon Oglenski maintains Frontier Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>) with a Overweight and raises the price target from $7 to $10.

ULCC

Barclays Maintains Overweight on Frontier Group Holdings, Raises Price Target to $10

WIIM

Intellicheck shares are trading lower after the company reported worse-than-expected Q3 financial result.

DOCN

DigitalOcean Launches Scalable Storage For Managed MongoDB, Enabling Independent Storage Scaling For Cost-Effective And Flexible Database Management

In the latest quarter, 6 analysts provided ratings for PROCEPT BioRobotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for PROCEPT BioRobotics, presenting an average target of $93.83, a high estimate of $105.00, and a low estimate of $75.00. Observing a 17.58% increase, the current average has risen from the previous average price target of $79.80. 
<img src="https://www.benzinga.com/files/images/story/2024/1731607262_0_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive PROCEPT BioRobotics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Sarcone</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$95.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Joshua Jennings</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$99.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Craig Bijou</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$94.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to PROCEPT BioRobotics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of PROCEPT BioRobotics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of PROCEPT BioRobotics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of PROCEPT BioRobotics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PRCT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on PROCEPT BioRobotics analyst ratings.</a>
<h2>Unveiling the Story Behind PROCEPT BioRobotics</h2>
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.
<h3>PROCEPT BioRobotics: A Financial Overview</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: PROCEPT BioRobotics's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 66.29%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: PROCEPT BioRobotics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -35.93%, the company may face hurdles in effective cost management.
Return on Equity (ROE): PROCEPT BioRobotics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -8.51%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): PROCEPT BioRobotics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -5.6%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.33, PROCEPT BioRobotics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Innovator ETFs Trust Innovator Premium Income 15 Buffer ETF - January

News

Latest news for Innovator ETFs Trust Innovator Premium Income 15 Buffer ETF - January (BATS:LJAN)

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga